DB
NVO

Dmitry Balyasny’s Novo Nordisk NVO Stock Holding History

Dmitry Balyasny’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.2M Buy
1,109,982
+726,836
+190% +$31.2M 0.07% 341
2026
Q1 		$14.1M Sell
383,146
-124,963
-25% -$5.92M 0.02% 855
2025
Q4 		$25.9M Buy
508,109
+464,129
+1,055% +$23.7M 0.03% 596
2025
Q3 		$2.44M Sell
43,980
-1,490,771
-97% -$87.3M ﹤0.01% 1711
2025
Q2 		$106M Buy
1,534,751
+1,227,342
+399% +$83.5M 0.16% 142
2025
Q1 		$21.3M Sell
307,409
-420,105
-58% -$34.7M 0.04% 571
2024
Q4 		$62.6M Buy
727,514
+202,223
+38% +$21.9M 0.09% 261
2024
Q3 		$62.5M Buy
525,291
+141,647
+37% +$18.9M 0.1% 236
2024
Q2 		$54.8M Buy
+383,644
New +$50.8M 0.1% 272
2024
Q1 		– Sell
-403,673
Closed -$41.8M – 2959
2023
Q4 		$41.8M Buy
+403,673
New +$39.9M 0.08% 315
2023
Q2 		– Sell
-209,098
Closed -$17.1M – 2629
2023
Q1 		$16.6M Buy
+209,098
New +$14.8M 0.04% 584
2021
Q3 		– Sell
-374,192
Closed -$15.7M – 2281
2021
Q2 		$15.7M Buy
+374,192
New +$14.5M 0.07% 365
2020
Q3 		– Sell
-725,616
Closed -$23.8M – 1502
2020
Q2 		$23.8M Sell
725,616
-208,840
-22% -$6.66M 0.21% 132
2020
Q1 		$28.1M Sell
934,456
-459,528
-33% -$13.7M 0.33% 71
2019
Q4 		$40.3M Sell
1,393,984
-475,736
-25% -$13.2M 0.24% 110
2019
Q3 		$48.3M Buy
1,869,720
+1,313,966
+236% +$33.2M 0.33% 64
2019
Q2 		$14.2M Buy
555,754
+289,080
+108% +$7.14M 0.09% 308
2019
Q1 		$6.97M Sell
266,674
-256,526
-49% -$6.3M 0.05% 485
2018
Q4 		$12.1M Sell
523,200
-53,284
-9% -$1.18M 0.09% 310
2018
Q3 		$13.6M Sell
576,484
-198,212
-26% -$4.84M 0.06% 396
2018
Q2 		$17.9M Buy
774,696
+181,136
+31% +$4.3M 0.08% 338
2018
Q1 		$14.6M Buy
+593,560
New +$15.6M 0.06% 409

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Dmitry Balyasny's NVO Position: Q2 2026 in Review

Dmitry Balyasny increased its Novo Nordisk (NVO) stake by 190% in Q2 2026, buying an estimated $31.2M and bringing the position to 1,109,982 shares worth $53.2M. The position accounts for 0.07% of the portfolio, ranked #341.

Dmitry Balyasny first reported a position in NVO in Q1 2018 and has held it in 22 quarters since. The position peaked at $106M in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Dmitry Balyasny held 1,109,982 shares of Novo Nordisk worth $53.2M as of Q2 2026.
  • Dmitry Balyasny bought 726,836 Novo Nordisk shares in Q2 2026, an estimated $31.2M.
  • Novo Nordisk made up 0.07% of Dmitry Balyasny's portfolio in Q2 2026, its #341 holding.
  • Dmitry Balyasny first reported a position in Novo Nordisk in Q1 2018 and has held it in 22 quarters since.
  • Dmitry Balyasny's Novo Nordisk position peaked at $106M in Q2 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.